SMARCB1 and neoplasm: Mouse models for SMARCB1 loss have verified a tumor suppressive role for this protein, with homozygous loss leading to frequent formation of lymphomas and RT-like tumors at only 11 weeks, which is notably faster than TP53-inactivated models of sarcoma (Guidi et al., 2001; Roberts et al., 2000; Wilson and Roberts, 2011).